Lactobacillus acidophilus Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses
Authors:
- Darby GilfillanDGDarby Gilfillan
- Allison C. VilanderAVAllison C. Vilander
- Meichen PanMPMeichen Pan
- Yong Jun GohYGYong Jun Goh
- Sarah O’flahertySOSarah O’flaherty
- Ningguo FengNFNingguo Feng
- Bridget E. FoxBFBridget E. Fox
- Callie LangCLCallie Lang
- Harry B. GreenbergHGHarry B. Greenberg
- Zaid AbdoZAZaid Abdo
- Rodolphe BarrangouRBRodolphe Barrangou
- Gregg A. DeanGDGregg A. Dean
Open Access
Abstract
Rotavirus diarrhea-associated illness remains a major cause of global death in children under five, attributable in part to discrepancies in vaccine performance between high- and low-middle-income countries. Next-generation probiotic vaccines could help bridge this efficacy gap. We developed a novel recombinant Lactobacillus acidophilus (rLA) vaccine expressing rotavirus antigens of the VP8* domain from the rotavirus EDIM VP4 capsid protein along with the adjuvants FimH and FliC. The upp-based counterselective gene-replacement system was used to chromosomally integrate FimH, VP8Pep (10 amino acid epitope), and VP8-1 (206 amino acid protein) into the L. acidophilus genome, with FliC expressed from a plasmid. VP8 antigen and adjuvant expression were confirmed by flow cytometry and Western blot. Rotavirus naïve adult BALB/cJ mice were orally immunized followed by murine rotavirus strain ECWT viral challenge. Antirotavirus serum IgG and antigen-specific antibody-secreting cell responses were detected in rLA-vaccinated mice. A day after the oral rotavirus challenge, fecal antigen shedding was significantly decreased in the rLA group. These results indicate that novel rLA constructs expressing VP8 can be successfully constructed and used to generate modest homotypic protection from rotavirus challenge in an adult murine model, indicating the potential for a probiotic next-generation vaccine construct against human rotavirus.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI141603, T32AI162691)
This publication has 62 references indexed in Scilit:
- Construction and Immunological Evaluation of Dual Cell Surface Display of HIV-1 Gag and Salmonella enterica Serovar Typhimurium FliC in Lactobacillus acidophilus for Vaccine DeliveryClinical and Vaccine Immunology, 2012
- IgA is important for clearance and critical for protection from rotavirus infectionMucosal Immunology, 2012
- Mucosal vaccine adjuvants updateClinical and Experimental Vaccine Research, 2012
- Assessment of Lactobacillus gasseri as a Candidate Oral Vaccine VectorClinical and Vaccine Immunology, 2011
- Directed Chromosomal Integration and Expression of the Reporter Gene gusA3 in Lactobacillus acidophilus NCFMApplied and Environmental Microbiology, 2011
- Dissimilar Properties of Two Recombinant Lactobacillus acidophilus Strains Displaying Salmonella FliC with Different Anchoring MotifsApplied and Environmental Microbiology, 2011
- Oral Vaccination with the Porcine Rotavirus VP4 Outer Capsid Protein Expressed byLactococcus lactisInduces Specific Antibody ProductionJournal of Biomedicine and Biotechnology, 2010
- Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in miceBMC Microbiology, 2009
- Development and Application of a upp -Based Counterselective Gene Replacement System for the Study of the S-Layer Protein SlpX of Lactobacillus acidophilus NCFMApplied and Environmental Microbiology, 2009
- Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigsVaccine, 2008